Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
advice, ANDA, augment, BBA, Becton, Bipartisan, blend, Blueprint, Cadillac, cellular, conference, Congressional, Dickinson, donut, DSCSA, exact, excise, feedback, FSS, gap, HHS, hole, incentivize, indefinite, intimal, Leaf, myofibroblast, NOL, Nonemployee, nurse, passed, pocket, reconciling, recoverability, searchable, signaling, step, sum, superseded, television, TJCA, Trump, unlimited, upregulation, Venture, Wholesale
Filing tables
Filing exhibits
Related press release
TARA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-222415) pertaining to the 2014 Equity Incentive Plan, the 2014 Employee Stock Purchase Plan, and the Amended and Restated 2006 Equity Incentive Plan of Proteon Therapeutics, Inc., |
(2) | Registration Statement (Form S-3 No. 333- 219676) of Proteon Therapeutics, Inc., |
(3) | Registration Statement (Form S-3 No.333- 228865) of Proteon Therapeutics, Inc., |
(4) | Registration Statement (Form S-8 No. 333-229123) pertaining to the Amended and Restated 2014 Equity Incentive Plan and the Amended and Restated 2014 Employee Stock Purchase Plan; |
and the related Prospectus of our report dated March 13, 2019, with respect to the consolidated financial statements of Proteon Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2018.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 13, 2019